pyrazines has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fuller, RW; Hemrick-Luecke, SK; Ward, JS | 1 |
| Du, J; Duan, H; Guo, B; Lee, SM; Wang, Y; Xu, D; Zhang, Z | 1 |
| Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L | 1 |
| Bi, L; Lu, C; Miao, Q; Miao, S; Shi, X; Wang, S; Xie, Y; Yang, Q; Zhang, J; Zhang, M; Zhang, S; Zhou, X | 1 |
4 other study(ies) available for pyrazines and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Potent in vivo but not in vitro inhibition of monoamine oxidase by 3-chloro-alpha-phenylpyrazinemethanol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzyl Alcohols; Brain; Corpus Striatum; Dopamine; Frontal Lobe; Isoenzymes; Kinetics; Liver; Male; Mice; Mice, Inbred Strains; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Myocardium; Norepinephrine; Pyrazines | 1992 |
Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Behavior, Animal; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Humans; Ligusticum; Male; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Oxidopamine; Parkinson Disease; Phytotherapy; Plant Extracts; Pyrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Substantia Nigra; Zebrafish | 2014 |
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; Antiparkinson Agents; Biological Availability; Cell Membrane Permeability; Dogs; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Hypersensitivity, Delayed; Levodopa; Macaca fascicularis; Madin Darby Canine Kidney Cells; Male; Microsomes, Liver; Models, Molecular; Parkinson Disease; Pyrazines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship | 2014 |
Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cytochromes c; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Down-Regulation; Glutamate-Cysteine Ligase; Male; MPTP Poisoning; Neuroprotective Agents; NF-E2-Related Factor 2; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rats, Wistar; Up-Regulation | 2014 |